Albuquerque: (505) 998-7400
Las Cruces: (575) 522-5752
Roswell: (575) 627-5828
Westside ABQ: (505) 998-7443
Alamogordo: (575) 446-5100
Clovis: (575) 769-7577
Clinical Trial Research
Ongoing Clinical Trial Studies
Novo Nordisk Trial
Sponsor: Novo Nordisk
Protocol: NN9838-4942
The cardiovascular safety and efficacy of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with established cardiovascular disease.
Traverse Trial
Sponsor: Travere
Protocol: TVTX-RE021-204
A multicentered, single-group phase 2, exploratory, open-label study to investigate safety and effect of sparsentan in combination with sodium glucose cotransporter-2 (SGLT2) inhibition in the treatment of adult participants with IDA nephropathy (IGAN)
Vera Therapeutics Trial
Sponsor: Vera Therapeutics
Protocol: VT-001-0050
A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN).
Vertex Pharmaceuticals Incorporated Trial
Sponsor: Vertex
Pharmaceuticals Incorporated
Protocol: VX21-147-301
A Phase 2/3 Adaptive, Double-blind, PlaceboControlled Study to Evaluate the Efficacy and Safety of VX- 147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease Vertex Study Number: VX21-147-301 IND Number: 141671.
Vertex Pharmaceuticals Incorporated Trial
Sponsor: Vertex Pharmaceuticals Incorporated
Protocol: VX19-NEN-801
A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin.
Shionogi Trial
Sponsor: Shionogi
Protocol: ACTIV-2D/A5407
A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S- 217622 compared with placebo in non-hospitalized participants with COVID-19.
AstraZeneca AB Trial
Sponsor: AstraZeneca AB
Protocol: D7000C00001 SuperNova
A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment
Closed for Enrollment
Contact Research Team Member